KARYOPHARM THERAPEUTICS INC. Karyopharm Therapeutics Inc. Share Price
Equities
KPTI
US48576U1060
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.07 USD | +4.90% |
|
-0.93% | +23.70% |
| 08/05 | Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Reports Q1 Revenue $33.1M, vs. Street Est of $34.5M | MT |
| 08/05 | Transcript : Karyopharm Therapeutics Inc., Q1 2024 Earnings Call, May 08, 2024 |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 145M 12.08B | Sales 2025 * | 166M 13.9B | Capitalization | 125M 10.4B |
|---|---|---|---|---|---|
| Net income 2024 * | -144M -12.02B | Net income 2025 * | -131M -10.94B | EV / Sales 2024 * | 0.86 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.75 x |
| P/E ratio 2024 * |
-0.88
x | P/E ratio 2025 * |
-1.08
x | Employees | 325 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.58% |
More Fundamentals
* Assessed data
More news
Latest transcript on Karyopharm Therapeutics Inc.
More recommendations
More press releases
| 1 day | +4.90% | ||
| 1 week | -0.93% | ||
| Current month | +3.88% | ||
| 1 month | -20.15% | ||
| 3 months | -20.15% | ||
| 6 months | +54.33% | ||
| Current year | +23.70% |
1 week
1.00
1.20
1 month
1.001.42
Current year
0.661.95
1 year
0.622.76
3 years
0.6214.73
5 years
0.6229.61
10 years
0.6249.01
| Managers | Title | Age | Since |
|---|---|---|---|
Richard Paulson
CEO | Chief Executive Officer | 56 | 26/20/26 |
Mike Mason
DFI | Director of Finance/CFO | 49 | 25/19/25 |
Amama Sadiq
CTO | Chief Tech/Sci/R&D Officer | - | 01/23/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Garen Bohlin
BRD | Director/Board Member | 76 | 03/13/03 |
Barry Greene
BRD | Director/Board Member | 60 | 01/13/01 |
| Director/Board Member | 59 | 01/13/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/24/09 | 1.07 | +4.90% | 1,503,994 |
| 08/24/08 | 1.02 | -7.27% | 2,639,086 |
| 07/24/07 | 1.1 | -4.35% | 990,027 |
| 06/24/06 | 1.15 | +1.77% | 848,584 |
| 03/24/03 | 1.13 | +4.63% | 983,372 |
Delayed Quote Nasdaq, May 10, 2024 at 01:30 am IST
More quotes
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Companyâs product candidate, eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
1.07
USD
Average target price
5.429
USD
Spread / Average Target
+407.34%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +23.70% | 125M | |
| +2.97% | 108B | |
| +10.21% | 104B | |
| +2.59% | 22.33B | |
| -12.77% | 22.19B | |
| -7.05% | 18.69B | |
| -38.36% | 17.74B | |
| -6.50% | 17.64B | |
| +6.00% | 14.05B | |
| +37.20% | 12.51B |
- Stock Market
- Equities
- KPTI Stock